Search

Researchers at Mustansiriyah University conducted a study comparing the levels of anti-Mullerian hormone in polycystic women after treatment with Clomid versus Letrozole for ovulation induction. The study involved 83 infertile women aged 18-35 with polycystic ovarian syndrome. Both drugs significantly decreased the levels of anti-Mullerian hormone, with Letrozole showing a slightly greater decrease than Clomid. The research was published in the Journal of the Pakistan Medical Association and has been peer-reviewed. [Extracted from the article]

A study conducted at Ankara University Faculty of Medicine explored the inter-cycle variability of Anti-Mullerian Hormone (AMH) levels and its implications for predicting controlled ovarian stimulation cycle outcomes. The research found that AMH levels can fluctuate significantly between menstrual cycles, potentially leading to misclassification of patients. Measuring AMH levels in the early follicular phase of the controlled ovarian stimulation cycle was shown to provide a more accurate prediction of the number of oocytes collected, aiding in clinical decision-making. The study included normal and poor responder women, with significant correlations observed between AMH levels and total oocyte count as well as mature oocyte count. [Extracted from the article]

Researchers from Shandong University of Traditional Chinese Medicine have identified a group of high-risk women with diminished ovarian reserve (DOR) who are 35 years old and undergoing assisted reproduction technology. By analyzing anti-Mullerian hormone (AMH) and antral follicle counts (AFC), the study found that these high-risk DOR patients had lower cumulative live birth rates compared to women with normal ovarian reserve but higher rates than those with DOR. The research highlights the importance of timely identification of this overlooked cohort to improve clinical pregnancy outcomes. [Extracted from the article]

A recent study conducted at AL Azhar University in Cairo, Egypt, focused on the role of the anti-Mullerian hormone (AMH) before and after laparoscopic excision of benign ovarian tumors. The study included 65 patients aged 18 to 44 years old and found a significant reduction in AMH levels after ovarian cystectomy. The researchers concluded that future studies should include more patients for a longer follow-up period to further investigate the changes in AMH levels post-surgery. [Extracted from the article]

A recent study conducted by the Eunice Kennedy Shriver National Institute of Child Health has found that female childhood cancer survivors are at risk of infertility due to gonadotoxic chemotherapy and radiation. The study analyzed the levels of anti-Müllerian hormone (AMH) in these survivors and found that AMH levels were higher with time since treatment and correlated with the risk level determined by the Oncofertility Pediatric Initiative Network (O-PIN). The study also found that AMH levels may return over time, even after receiving high-risk therapy. These findings can help in counseling cancer patients before and after therapy. [Extracted from the article]

A new report from researchers at George Emil Palade University of Medicine in Romania explores the role of anti-Mullerian hormone (AMH) in regulating ovarian follicle development and female fertility. The study examined 52 non-polycystic-ovary-syndrome (PCOS) euthyroid women undergoing in vitro fertilization (IVF) and found that AMH levels were negatively correlated with age and follicle-stimulating hormone (FSH), while positively correlated with estradiol and total testosterone. However, no significant correlations were found between AMH levels and body mass index (BMI), luteinizing hormone (LH), or vitamin D levels. The researchers concluded that a holistic approach, considering factors such as age, weight, hormonal balance, nutrition, and thyroid health, is necessary to better understand and manage ovarian reserve. [Extracted from the article]

A recent study conducted by researchers at Juntendo University in Tokyo, Japan, explores the role of anti-Mullerian hormone receptor type 2 (AMHR2) in non-small cell lung cancer (NSCLC). The study found that 5%-8% of NSCLCs exhibit high AMHR2 expression, suggesting that AMH may inhibit the progression of some lung cancers. Immunostaining and gene expression analysis revealed that activation of the AMH-AMHR2 pathway suppressed cell proliferation in lung adenocarcinoma tissues. These findings contribute to a better understanding of the clinical relevance of AMHR2 expression and its potential role in lung cancer treatment. [Extracted from the article]

A report from the Jordan University of Science & Technology discusses a rare case of Persistent Mullerian Duct Syndrome (PMDS) in a male child in Syria. PMDS is a condition where individuals have male external features but also possess female reproductive organs. The case study highlights the importance of early diagnosis and investigations in managing and preventing complications of this syndrome. However, the research faced obstacles due to a lack of cooperation from parents and the costs of further investigations. The report emphasizes the need for surgical intervention as the primary treatment approach for PMDS. [Extracted from the article]

A study conducted by Shanghai Jiao Tong University School of Medicine in China evaluated the performance of a novel fluorescent immunoassay for anti-Mullerian hormone (AMH) and established reference intervals for Chinese children. The study found that the assay showed good analytical performance and determined AMH reference ranges for different age groups and genders. The AMH levels were found to be high in males at birth and decreased with age, while in females, the levels were low at birth and increased with age. The findings may have implications for the clinical diagnosis and treatment of related diseases. [Extracted from the article]

A recent study conducted in West Bengal, India, explored the correlation between reproductive hormones and age in women with ovarian cysts. The study found a strong negative correlation between follicle-stimulating hormone (FSH) and anti-Mullerian hormone (AMH), as well as between age and AMH. A weak negative correlation was observed between AMH and antral follicle count (AFC). The presence of ovarian cysts did not affect AMH or AFC, but it significantly reduced FSH values. The researchers concluded that FSH and AFC could be reliable markers for ovarian reserve testing in resource-limited settings, while the combination of FSH, AMH, and AFC could be more effective in tertiary centers with greater resources. [Extracted from the article]

A study conducted by researchers at Capital Medical University in Beijing, China, aimed to establish a cutoff level of anti-Mullerian hormone (AMH) that could aid in the diagnosis of polycystic ovary syndrome (PCOS) in Chinese women. The study involved 550 women, including 450 with PCOS and 100 without PCOS. The researchers found that the combination of AMH and free testosterone had a high accuracy in predicting PCOS, with a sensitivity of 86.1% and specificity of 90.3%. The study concluded that the Elecsys AMH Plus immunoassay, with a cutoff of 4.64 ng/mL, is a reliable method for identifying PCOS. [Extracted from the article]

This document provides information about a clinical trial, NCT06525155, that is currently being conducted in Indonesia to study the effectiveness of triptorelin in treating endometriosis. Endometriosis is a chronic disease that affects a significant number of women and causes pelvic pain. Triptorelin has shown promise in treating the symptoms of endometriosis, but patient compliance is low due to cost and side effects. The trial will compare two groups receiving triptorelin at different intervals and measure pain levels, hormone levels, and evaluate the condition of the uterus and cysts during surgery. The study is currently recruiting participants and is projected to be completed in December 2024. [Extracted from the article]

A new report from the Department of Obstetrics and Gynecology in Cerdanyola del Valles, Spain, presents fresh data on the predictive value of anti-Mullerian hormone (AMH) for clinical pregnancy in non-infertile women undergoing intrauterine insemination with donor sperm (ds-IUI). The study found that AMH levels were not a reliable predictor of pregnancy success in these women. Even women with low AMH levels were able to achieve successful pregnancy outcomes, suggesting that diminished ovarian reserve should not restrict access to ds-IUI treatments in eligible non-infertile women. This research has been peer-reviewed. [Extracted from the article]

A study conducted by researchers in Australia found that providing women with accurate information about the anti-Mullerian hormone (AMH) test, which indicates the number of eggs in their ovaries, reduced their interest in taking the test compared to women who viewed information available online. The researchers conducted an online randomized controlled trial with 967 women aged 25-40 who had never had an AMH test. Those who received evidence-based information about the test had less interest in taking it, while those who viewed information from an existing website had more interest. The study highlights the importance of providing women with accurate information about the limitations of the test. [Extracted from the article]

A recent study conducted by researchers from Alexandria University evaluated the diagnostic value of different serum biomarkers in girls with central precocious puberty. The researchers found that basal serum luteinizing hormone outperformed follicle-stimulating hormone and anti-Mullerian hormone as a screening tool for central precocious puberty. This finding suggests that basal luteinizing hormone could potentially reduce the need for the expensive and challenging GnRH stimulation test. The study provides valuable insights into the diagnosis of early puberty in girls and offers an alternative approach for healthcare professionals. [Extracted from the article]

A recent study conducted at the University of Health Sciences in Istanbul, Turkey, examined the effects of obesity on clinical outcomes in women with diminished ovarian reserve (DOR) undergoing intracytoplasmic sperm injection cycles. The study found that obesity was associated with higher doses of gonadotropins, longer days of ovarian stimulation, and a lower number of mature oocytes. However, obesity did not have a negative impact on the clinical pregnancy rate. This research provides valuable insights into the relationship between obesity and reproductive outcomes in women with DOR. [Extracted from the article]

A study conducted by researchers from the University of Lille in France explores the role of anti-Mullerian hormone (AMH) in male reproduction and sperm motility. AMH is secreted by Sertoli cells and is responsible for the regression of Mullerian ducts in male fetuses during sexual differentiation. Serum AMH concentrations are lowest in the first days after birth but increase after the first week, reflecting active Sertoli cell proliferation. AMH levels rise rapidly in boys during the first month, reaching a peak at around 6 months of age, and remain high during childhood before slowly declining during puberty. AMH measurement is used as a marker of immature Sertoli cell number and function in childhood and has gained attention in research on male fertility-related disorders. The study reviews and summarizes the potential contribution of serum AMH measurement in these disorders. [Extracted from the article]

A study conducted at Foundation University Medical College in Pakistan explored the use of Anti-Mullerian hormone (AMH) as a diagnostic marker for Polycystic Ovary Syndrome (PCOS). The study recruited 30 cases of PCOS and 30 age-matched controls, measuring AMH and testosterone levels in both groups. The researchers found that AMH can be used as an independent screening marker for PCOS, with an optimal cut-off point of 3.22ng/mL. This finding could potentially reduce inconvenience and financial burden for patients and the healthcare system. [Extracted from the article]

A recent study conducted at Yazd University in Iran explored the relationship between anti-Mullerian hormone (AMH) levels and the success of assisted reproductive technology (ART) in a large Iranian population. The study analyzed data from 1000 infertile couples undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The researchers found that higher serum AMH levels in the early follicular phase were associated with better ovarian reserve and shorter ART cycles. This research provides valuable insights into the role of AMH as a predictor of ovarian response in ART. [Extracted from the article]

Peking University Third Hospital in China is conducting a clinical trial, NCT06481969, to examine the effectiveness and safety of autologous adipose stromal vascular fraction (SVF) in improving pregnancy outcomes for infertile patients with premature ovarian insufficiency (POI). The trial will enroll 260 patients diagnosed with POI and will compare the SVF protocol with a conventional protocol. The study will last approximately 2 years and will measure various outcomes such as pregnancy rates, hormone levels, and adverse reactions. This document provides information about the study, including recruitment details and contact information. [Extracted from the article]

A recent study conducted by researchers at the Cancer Research Institute explored the potential protective effect of vitamin D on ovarian reserve in breast cancer patients undergoing chemotherapy. The study involved 33 patients and found that there was no significant improvement in anti-Mullerian hormone (AMH) levels after six months of chemotherapy in the group that received vitamin D supplementation compared to the control group. The researchers concluded that further larger studies are needed to evaluate the effect of vitamin D supplements on ovarian reserve in breast cancer patients undergoing chemotherapy. [Extracted from the article]

A study conducted by researchers at Harvard Medical School examined the associations between anti-Mullerian hormone (AMH) levels in women in their mid-30s and menopausal symptoms 14 years later. The study included 474 participants who were enrolled during pregnancy between 1999 and 2002. The results showed that lower AMH levels in the mid-30s were associated with earlier menopause and increased odds of vaginal dryness, but fewer psychological symptoms. This research was supported by the National Institutes of Health (NIH) and has been peer-reviewed. [Extracted from the article]

A study conducted at University Hospital Tours in France has established reference values for anti-Mullerian hormone (AMH) in pediatrics using the Fujirebio Lumipulse G AMH assay. The study compared the Fujirebio Lumipulse G AMH assay with the Roche Elecsys AMH assay and found that the Fujirebio method showed excellent correlation but had a positive bias. The research concluded that AMH concentrations can be valuable clinical tools for monitoring pediatric sexual and reproductive development. The study provides full pediatric gender and age-specific reference ranges for AMH using the Fujirebio Lumipulse G AMH assay. [Extracted from the article]

A study conducted by the University of Babylon in Iraq examined the effectiveness of measuring Anti-Mullerian Hormone (AMH) and Follicle Stimulating Hormone (FSH) levels in predicting ovarian response in infertile women undergoing controlled ovarian stimulation. The study involved 90 female participants with primary and secondary infertility. The results showed that AMH was a better predictor of ovarian response compared to FSH. AMH demonstrated a negative correlation with age and a positive correlation with antral follicle count, total number of follicles, and retrieved oocyte count. The study suggests that AMH can be a useful marker in assessing ovarian response in infertile women. [Extracted from the article]

A study conducted in South India explored the association between serum vitamin D and anti-Mullerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS). The study included 120 women with PCOS and 60 controls. The results showed no significant difference in vitamin D levels between the PCOS and control groups. However, there was a weak positive correlation between vitamin D levels and AMH levels in the PCOS group. The study concluded that AMH levels were independently correlated with age, but not with vitamin D. [Extracted from the article]

A recent study conducted by researchers at Vrije Universiteit Amsterdam examined the impact of the EuroNet-PHL-C2 treatment protocol on gonadal function in girls with classical Hodgkin lymphoma (cHL). The study found that serum anti-Müllerian hormone (AMH) levels decreased after induction chemotherapy but increased during subsequent treatment and 2 years of follow-up. However, patients treated for advanced stage cHL had lower AMH levels compared to those with early or intermediate stage disease. The study suggests that while the EuroNet-PHL-C2 protocol remains below the cut-off for high risk of infertility, not all girls recovered to pre-treatment AMH levels, particularly those with advanced cHL. Further research is needed to explore the long-term reproductive outcomes of survivors treated with this protocol. [Extracted from the article]

A recent study conducted at the Shenzhen Traditional Chinese Medicine Hospital in China explored the relationship between anti-Mullerian hormone (AMH) levels, reproductive factors, and osteoporosis in women. The study used Mendelian randomization analysis to determine causal associations. The findings indicated that age at menarche and age at natural menopause were genetically causally associated with decreased bone mineral density (BMD), but not with osteoporosis. AMH levels and other reproductive factors were not found to be causally related to BMD or osteoporosis. This research provides valuable insights into the genetic predictors of osteoporosis in women. [Extracted from the article]

A clinical trial has been launched to investigate the therapeutic efficacy of dihydroartemisinin in patients with polycystic ovary syndrome (PCOS). The primary research hypothesis is that dihydroartemisinin can restore regular menstrual cycles in PCOS patients who meet at least two of the three Rotterdam Criteria. Secondary research hypotheses include the reduction of androgen levels, total immature follicles, and anti-Mullerian hormone. The study aims to explore the effects of dihydroartemisinin in PCOS patients who meet at least two of the Rotterdam Criteria. The trial is currently recruiting participants in China. [Extracted from the article]

A recent study conducted by researchers at the University of Arizona has found that women with endometriosis have lower levels of anti-Müllerian hormone (AMH), which is associated with ovarian reserve, compared to women without the condition. The study, which included 1,961 premenopausal women, found that those with endometriosis had 29.6% lower AMH levels than those without. The researchers suggest that this may be one mechanism through which endometriosis influences infertility, younger age at menopause, and cardiovascular disease. Further research is needed to explore the long-term effects of endometriosis on AMH levels in the general population. [Extracted from the article]

A recent report from the Department of Obstetrics and Gynecology discusses the impact of ovarian endometrioma and endometriotic cystectomy on anti-Mullerian hormone (AMH) and antral follicle count (AFC), which are measures of ovarian reserve in women with ovarian endometrioma. The report found that endometriotic cystectomy, particularly the stripping technique, negatively affects ovarian reserve in the short and long term. The damage to ovarian reserve is more pronounced in bilateral cases compared to unilateral cases. The report suggests that AMH should be the preferred biomarker for counseling and managing women with endometrioma before surgery. However, further research is needed to increase the level of evidence and address remaining questions. [Extracted from the article]

A recent report from Kasturba Medical College discusses the potential benefits of intra-ovarian injection of platelet-rich plasma (PRP) for women with poor ovarian response (POR) or premature ovarian insufficiency (POI). The study analyzed the effects of PRP on pregnancy rates, oocyte and embryo formation, and ovarian reserve markers such as antral follicular count and anti-Mullerian hormone. The findings suggest that PRP injection may have a moderate level of evidence in improving these outcomes. However, further randomized studies are needed to confirm these results. [Extracted from the article]

A recent study conducted by researchers at Korea University College of Medicine compared the impact on ovarian reserve after minimally invasive ovarian cystectomy using two platforms: the Da Vinci robotic system (Xi and SP) and the laparoscopic system. The study found that there were no significant differences in preoperative age, cyst size, estimated blood loss, hospital stay, adhesion detachment rate, and cyst rupture rate between the two groups. However, the laparoscopic group had a significantly shorter operative time. The study also found that the Da Vinci robotic system was not inferior to the laparoscopic system in preserving ovarian function. [Extracted from the article]

This document provides information about a clinical trial being conducted at the West China Second University Hospital in China. The trial aims to compare different methods of hemostasis during laparoscopic ovarian cystectomy in women with benign ovarian cysts. The study will involve 165 participants and is expected to be completed by June 2026. The eligibility criteria for participants are outlined, and the contact information for the primary investigator is provided. The document also includes keywords related to the study, such as gynecology, women's health, and clinical research. [Extracted from the article]

A study conducted at Peking Union Medical College Hospital in Beijing, China, aimed to investigate the risk factors associated with a decrease in ovarian reserve in patients with endometriomas after laparoscopic cystectomy. The study analyzed the levels of anti-Mullerian hormone (AMH) and other clinical data from 233 patients with endometriomas and 57 patients with non-endometrioma ovarian cysts. The results showed that older age, higher body mass index (BMI), and shorter menstrual cycles were associated with decreased AMH levels in patients with endometriomas. Additionally, patients with bilateral cysts, advanced surgical staging, or a completely enclosed Douglas pouch had significantly lower AMH levels. The study concluded that laparoscopic removal of endometriomas can adversely affect ovarian reserve, and it is important to conduct thorough patient evaluations and provide comprehensive patient education for appropriate fertility preservation guidance. [Extracted from the article]

A recent study conducted at Dhaka Medical College Hospital in Bangladesh explored the relationship between hypothyroidism and ovarian reserve in infertile women. The researchers found that impaired thyroid function can affect follicular growth and development, leading to a reduction in the number of follicles in the ovaries. The study also revealed a negative association between anti-thyroid antibodies and anti-Mullerian hormone, suggesting that hypothyroidism has a negative effect on ovarian reserve. These findings highlight the importance of considering thyroid function in the evaluation and treatment of infertility in women. [Extracted from the article]

A recent study conducted by researchers at Shahid Beheshti University of Medical Sciences investigated the effects of metformin on anti-Mullerian hormone (AMH) levels in women with polycystic ovarian syndrome (PCOS). The study analyzed data from 16 controlled trials involving 484 participants. The findings showed that metformin significantly reduced AMH levels in both single-arm and randomized clinical trials. The study concluded that metformin treatment has a beneficial effect on reducing AMH levels in women with PCOS. Further details of the study can be found in the BMC Endocrine Disorders journal. [Extracted from the article]

A scoping review conducted by researchers at Radboud University Nijmegen in the Netherlands explores the fertility dilemmas faced by girls with Turner Syndrome (TS), a genetic condition where individuals lack a partial or complete sex chromosome. The review highlights the importance of assessing a girl's fertility potential and providing comprehensive counseling on family planning options from an early age. The study also discusses the role of anti-Mullerian hormone (AMH) in estimating ovarian function and the increasing use of fertility preservation techniques such as oocyte vitrification and ovarian tissue cryopreservation. However, the research notes that only a minority of girls with TS receive specialized counseling on fertility, and there is a need for a reliable prognostic model to determine which girls might benefit from fertility preservation. [Extracted from the article]

A recent study conducted in Singapore focused on the impact of age and lifestyle on anti-Mullerian hormone (AMH) levels and ovarian reserve in Asian women with and without polycystic ovary syndrome (PCOS). PCOS affects 4-20% of women of reproductive age and is a common cause of infertility. The study found that elevated AMH levels are associated with PCOS, but an exact cut-off value remains elusive. The research suggests that lifestyle modifications, such as maintaining a healthy BMI and quitting smoking, may have beneficial effects for Asian women with PCOS. [Extracted from the article]

A recent study conducted at Cairo University in Egypt explored the levels of anti-Mullerian hormone (AMH) and inhibin-B in cases of non-obstructive azoospermia (NOA) and obstructive azoospermia (OA). The study found that inhibin-B levels were significantly lower in NOA cases compared to OA cases and controls. Additionally, there were positive correlations between AMH and inhibin-B, as well as between inhibin-B and free testosterone (FT) and weak correlation between beta inhibin and luteinizing hormone (LH). The study suggests that inhibin-B is expressed by Leydig cells and has correlations with FT and LH. [Extracted from the article]

A recent study conducted by researchers at the University of Paris Saclay has found that anti-Mullerian hormone (AMH) induces autophagy, a cellular process that helps preserve the pool of primordial follicles (PMFs) in mice. AMH is known for its inhibitory role in the growth of PMFs, but this study reveals its additional role in promoting their survival through autophagy activation. The researchers observed a decrease in the phosphorylation of the FOXO3A transcription factor and an increase in autophagy in mouse ovaries treated with AMH. These findings suggest that AMH protects the ovarian reserve by inhibiting follicular growth and inducing autophagy. [Extracted from the article]

A recent study conducted by researchers at the Faculty of Medicine Universitas Padjadjaran in Indonesia explored the correlation between pre-chemotherapy Anti-Mullerian Hormone (AMH) levels, menstrual status, and the prediction of ovarian function recovery in pre-menopausal women with breast cancer. The study found that there was a significant difference in AMH levels before and after six cycles of chemotherapy, with lower levels observed after treatment. Additionally, there was a high correlation between pre-chemotherapy AMH levels and menstrual status six months after treatment. The researchers concluded that AMH levels could be used to predict ovarian function recovery in these patients. [Extracted from the article]

A recent study conducted by the Instituto Nacional de Cancer in Rio de Janeiro, Brazil, explored the impact of radioiodine (RAI) treatment on the female reproductive system in patients with pediatric differentiated thyroid cancer (DTC). The study found that serum anti-Mullerian hormone (AMH) levels were lower in patients who received multiple RAI doses, particularly those who had a cumulative RAI dose above 200 mCi. The findings suggest that further research is needed to fully understand the effects of RAI on fertility, taking into account cumulative activity and treatment strategies. This information may be valuable for individuals researching thyroid cancer and its treatment options. [Extracted from the article]

A recent study conducted by researchers at the DOW University of Health Sciences in Karachi, Pakistan, has provided new insights into Persistent Mullerian Duct Syndrome (PMDS), a rare male disorder of sexual development. PMDS is characterized by the presence of female internal organs in phenotypically and genotypically male individuals due to a deficiency of anti-mullerian hormone or insensitivity of tissues to this hormone. The study presented a case report of a 19-year-old male who was diagnosed with bilateral cryptorchidism and a rudimentary uterus. The patient underwent laparoscopic surgery to remove the rudimentary uterus after a trial of stepwise orchidopexy followed by orchidectomy. This research has been peer-reviewed and published in the Journal of the Pakistan Medical Association. [Extracted from the article]

A recent study from Brigham and Women's Hospital explores the use of assisted reproductive technology (ART) in people with epilepsy. The study discusses the hormonal influences on epilepsy and catamenial epilepsy, fertility considerations for women with epilepsy, and management considerations for people with epilepsy undergoing ART. The research suggests that ART can be an effective treatment for individuals with epilepsy who want to conceive, but closer monitoring and adjustments to antiseizure medication may be necessary for optimal outcomes. However, more research is needed to better understand the impact of ART on seizure frequency and medication levels. [Extracted from the article]

A recent study conducted at Suez Canal University in Egypt compared the effects of Dienogest therapy and laparoscopic cystectomy on ovarian reserve in women with endometriomas. The study found that Dienogest therapy increased ovarian reserve, as measured by antral follicle count and serum anti-mullerian hormone, while surgical excision decreased ovarian reserve. Both treatment options resulted in a reduction in pelvic pain. The researchers concluded that Dienogest therapy can help preserve ovarian reserve in women with endometriomas. Further information on the study can be found in the Journal of Endometriosis and Pelvic Pain Disorders. [Extracted from the article]